BioCryst ( (BCRX) ) just unveiled an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BioCryst Pharmaceuticals, Inc. has landed a significant contract with the U.S. Department of Health and Human Services worth up to $69 million for the supply of RAPIVAB® (peramivir injection), an influenza treatment, over the next five years. This contract is intended to bolster the nation’s Strategic National Stockpile for public health emergencies. The agreement includes an initial 12-month base period with four subsequent optional 12-month periods. The first order, worth $13.9 million for 19,125 doses, has already been placed and is expected to be fulfilled by September 2025. However, the company cautions that there are risks, including potential lower demand or manufacturing issues that could affect the contract’s fulfillment.
For an in-depth examination of BCRX stock, go to TipRanks’ Stock Analysis page.